Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc_20100114

Ironwood Pharmaceuticals Inc patents


Recent patent applications related to Ironwood Pharmaceuticals Inc. Ironwood Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Ironwood Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Ironwood Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Ironwood Pharmaceuticals Inc-related inventors


Sgc stimulators

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of... Ironwood Pharmaceuticals Inc

Methods of treating upper gastrointestinal disorders in ppi refractory gerd

Disclosed herein are oral dosage forms of colesevelam, or a pharmaceutically acceptable salt thereof, adapted to treat upper gastro-intestinal disorders associated with PPI refractory GERD. Also disclosed are the methods of using these oral dosage forms to treat upper gastrointestinal disorders associated with PPI refractory, or PPI resistant, GERD in... Ironwood Pharmaceuticals Inc

Low-dose stable formulations of linaclotide

The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.... Ironwood Pharmaceuticals Inc

Salts, co-crystals, and polymorphs of an anxiolytic compound

The present invention provides crystalline Forms FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and related methods of treating and/or preventing a disease, such as a central nervous system disease (e.g., an anxiety disorder), using a crystalline Form FUM-P3, FUM-P4, MLA-P3 and MLA-P4 of compound formula 1 and/or pharmaceutical... Ironwood Pharmaceuticals Inc

Imidazotriazinone compounds

The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9 and pharmaceutically acceptable salt thereof. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.... Ironwood Pharmaceuticals Inc

Sgc stimulators

Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.... Ironwood Pharmaceuticals Inc

Sgc stimulators

wherein ring D, ring A, JB, n, J, RC1, RC2, Z1, Z2, W, X, Y1, Y2, JF and R9 are as defined herein.... Ironwood Pharmaceuticals Inc

Compositions comprising bile acid sequestrants for treating esophageal disorders

Disclosed herein are novel compositions and methods for treating or preventing upper GI tract disorders and protecting stratified squamous epithelium against injury by a noxious substance. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile... Ironwood Pharmaceuticals Inc

Pyrazole derivatives as sgc stimulators

Compounds are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.... Ironwood Pharmaceuticals Inc

Sgc stimulators

wherein ring D, ring A, ring E, ring F, JB, n, JD, o, RC1, RC2, W, JE, r, JF, s, Z1, Z2 and Z3 are as defined herein.... Ironwood Pharmaceuticals Inc

Treatment of constipation-predominant irritable bowel syndrome

The invention provides methods for treating a patient with constipation-predominant irritable bowel syndrome by administering a therapeutically effective dose of linaclotide.... Ironwood Pharmaceuticals Inc

Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant

Disclosed herein are novel compositions and methods for controlling the release of bile acid sequestrant to the stomach in order to treat or prevent upper GI tract disorders or disorders of the throat. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a... Ironwood Pharmaceuticals Inc

Low-dose stable formulations of linaclotide

The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.... Ironwood Pharmaceuticals Inc

Imidazotriazinone compounds

The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of PDE9 associated diseases or disorders in mammals, including humans.... Ironwood Pharmaceuticals Inc

Sgc stimulators

Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.... Ironwood Pharmaceuticals Inc

Sgc stimulators

Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.... Ironwood Pharmaceuticals Inc

Sgc stimulators

Compounds of Formula IA and Formula IB are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.... Ironwood Pharmaceuticals Inc

Sgc stimulators

wherein ring B, JB, n, JD, J, o, X, RC and RA are as described herein.... Ironwood Pharmaceuticals Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Ironwood Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Ironwood Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###